Thuong Vo, MD
Pain Medicine · Lancaster, CANPI 1760496574
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,569 of the $2,461 with a category attached, or 63.7%. It is spread thinly across 17 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2022 at $1,196 and has fallen 62.8% since, to $445 in 2025.
Across 60 payments — averaging $41.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$591
- Baxter Healthcare$480
- Amgen$413
- Boston Scientific$204
- GRT US Holding, Inc.$187
- Novo Nordisk$121
- plus $466 from 11 others
Across 10 payments — averaging $6055.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$61K
What the payments were for
- Travel & lodging$39216%
- Food & beverage$1,56964%
- Education$211%
- Other$48020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 11 | $591 |
| Baxter Healthcare | 1 | $480 |
| Amgen | 27 | $413 |
| Boston Scientific | 3 | $204 |
| GRT US Holding, Inc. | 1 | $187 |
| Novo Nordisk | 1 | $121 |
| Vertiflex, Inc. | 1 | $81 |
| Heron Therapeutics, Inc. | 1 | $69 |
| Nevro Corp. | 1 | $64 |
| Biodelivery Sciences International, Inc. | 4 | $58 |
| Novartis | 1 | $49 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Vision Quest Industries Inc. | 2 | $25 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Pfizer | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTABLATE$357
- mild Device Kit$357
- Qutenza$187
- WATCHMAN Access System$170
- Ozempic$121
How this compares
$2,461 in reported general payments places this provider in the 55th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 63 | $41,488 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 942 | $24,807 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 377 | $10,020 |
| Xtampza ErOxycodone Myristate | 11 | $6,839 |
| Morphine Sulfate ErMorphine Sulfate | 254 | $6,467 |
| Naloxone Hcl | 79 | $4,337 |
| Fentanyl | 27 | $3,045 |
| Celecoxib | 95 | $2,228 |
| Gabapentin | 177 | $1,945 |
| Pregabalin | 57 | $1,424 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 76 | $1,415 |
| Lidocaine | 16 | $1,326 |
| Hydromorphone Hcl | 76 | $1,224 |
| Cyclobenzaprine Hcl | 113 | $1,065 |
| Baclofen | 72 | $1,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAMorphine Sulfate | $21 | $42015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 pain medicine providers in California.
Other pain medicine in Lancaster
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.